Search for: "Kirin v. Kirin"
Results 41 - 60
of 83
Sort by Relevance
|
Sort by Date
5 Apr 2016, 6:32 am
A third case to watch out for is Novartis's Aclasta (zoledronic acid) patent with Swiss-type claims for the use of zoledronic acid in a once-yearly i/v administration for the treatment of osteoporosis. [read post]
25 Mar 2016, 2:11 pm
FKB, a joint venture between FUJIFILM and Kyowa Hakko Kirin, intends to clear the path of AbbVie's follow-on patents in order to market its biosimilar adalimumab product after expiry of the UK SPC in October 2018. [read post]
26 Nov 2015, 8:12 am
Per the precedent set in Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2004] UKHL 46 (and other cases since), the question is "...what the person skilled in the art would have understood the Patentee to be using the language of the claim to mean". [read post]
30 Jul 2015, 9:50 am
That is what today's decision addresses.Appeal to the Supreme CourtThe Court of Appeal has refused leave for Smith & Nephew to appeal to the Supreme Court, because it considered that there is no significant point of general public importance at stake, since it has done no more than apply the established principles of claim construction from Kirin Amgen (Kirin Amgen Inc v Hoechst Marion Roussel Ltd [2004] UKHL 46, [2005] RPC 9) to the case before it. [read post]
26 Jun 2015, 12:30 am
This Kat blogged last year about the masterful and erudite judgment of Mr Justice Arnold in the case of Actavis v Lilly (judgment on BAILII here), concerning pemetrexed. [read post]
13 May 2015, 7:58 am
Oliva et al. v. [read post]
29 Apr 2015, 7:24 pm
The class action lawsuit (Parent v. [read post]
26 Jan 2015, 9:57 pm
Category: Civil Procedure By: Roy Rabindranath, Contributor TitleJapanese Found. for Cancer Research v. [read post]
12 Dec 2014, 5:06 am
It won’t do if you are thinking of claim where the product is not actually new as such (such as erythropoietin in the Kirin Amgen case). [read post]
10 Dec 2014, 12:31 am
What Birss J has now done is to say "The EPO approach to the interpretation is a novelty rule, not a construction rule, and Kirin-Amgen shows that to be so". [read post]
12 Aug 2014, 9:55 pm
By Ralph Cox* and Simon Spink** -- Overview For the best part of 10 years, since the judgment of Lord Hoffmann in Kirin-Amgen v Hoescht Marion Roussel[1], it has been widely assumed that there is no file wrapper estoppel in the UK and no doctrine of equivalents either. [read post]
15 May 2014, 11:40 am
Kirin-Amgen might perhaps be regarded as an example of this. [read post]
19 Mar 2014, 9:00 am
It has been 15 years since the last brand v brand challenge of a biologic patent in Canada. [read post]
1 Jan 2014, 4:33 am
According to the recent Generics v Teva/Yeda decision, the burden of proof should therefore be on the alleged infringer, not the patentee. [read post]
14 May 2013, 12:22 am
The subject of Norman's guest post here is the recent US decision in CLS Bank Int’l v Alice Corp 2011-1301 (Fed Cir 2013) en banc aff’g 768 F Supp 2d 221 (D.D.C. 2011). [read post]
18 Apr 2013, 3:37 am
But this is a narrow exception to the general rule that a person will not be bound by the outcome of proceedings to which he is not a party: Skyparks v Marks, Powell v Wiltshire, Seven Arts v Content. iii) A direct commercial interest in the outcome of the litigation is insufficient to make someone a privy: Kirin-Amgen v Boehringer Mannheim. iv) Whether members of the same group of companies are privies or not depends on the facts: Special Effects. [read post]
5 Mar 2013, 11:03 pm
In true anecdotal style, the author explains the relevance of Section 115 of the Indian statute (appointment of scientific advisors) by pointing out the open expression of gratitude by Lord Hoffmann in Kirin-Amgen v. [read post]
20 Aug 2012, 4:31 am
., AND KYOWA HAKKO KIRIN CO. [read post]
10 Aug 2012, 8:33 am
" (Virgin v Premium Aircraft). [read post]
18 Jul 2012, 4:52 am
" "The second is that it is necessary to distinguish between claims that are difficult to construe or that have a "fuzzy boundary" (in the words of Lord Hoffmann in Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2004] UKHL 46, [2005] RPC 9 at [126]) on the one hand from claims that are truly ambiguous on the other. [read post]
